0.95% to Target, Cantor Fitzgerald Reaffirms Hold Rating for Biogen (BIIB) Stock; American Physicians Service Group (AMPH) Sentiment Is 1.15

April 26, 2018 - By Martha Paddon

Biogen Inc. (NASDAQ:BIIB) Logo

In an analyst note sent to investors on 25 April, Biogen Inc (NASDAQ:BIIB) stock Hold was restate at Cantor Fitzgerald. They currently have a $272.0000 PT on the stock. Cantor Fitzgerald’s PT means a potential upside of 0.95% from the company’s last stock close.

American Physicians Service Group Inc (AMPH) investors sentiment increased to 1.15 in Q4 2017. It’s up 0.24, from 0.91 in 2017Q3. The ratio is better, as 47 active investment managers started new and increased equity positions, while 41 decreased and sold positions in American Physicians Service Group Inc. The active investment managers in our database now own: 20.28 million shares, up from 20.04 million shares in 2017Q3. Also, the number of active investment managers holding American Physicians Service Group Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 36 Increased: 31 New Position: 16.

The stock increased 0.16% or $0.03 during the last trading session, reaching $19.28. About 66,622 shares traded. Amphastar Pharmaceuticals, Inc. (AMPH) has risen 29.43% since April 26, 2017 and is uptrending. It has outperformed by 17.88% the S&P500.

Argent Capital Management Llc holds 0.15% of its portfolio in Amphastar Pharmaceuticals, Inc. for 229,740 shares. Matarin Capital Management Llc owns 52,417 shares or 0.08% of their US portfolio. Moreover, Piermont Capital Management Inc. has 0.08% invested in the company for 12,730 shares. The New York-based Rothschild Asset Management Inc has invested 0.07% in the stock. Federated Investors Inc Pa, a Pennsylvania-based fund reported 1.05 million shares.

Analysts await Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report earnings on May, 14. They expect $0.09 EPS, up 200.00% or $0.06 from last year’s $0.03 per share. AMPH’s profit will be $4.19 million for 53.56 P/E if the $0.09 EPS becomes a reality. After $0.10 actual EPS reported by Amphastar Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.00% negative EPS growth.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $898.50 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It has a 214.22 P/E ratio. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $57.01 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 22.6 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

Since January 9, 2018, it had 0 insider purchases, and 5 insider sales for $2.87 million activity. Another trade for 1,294 shares valued at $386,712 was made by Sandrock Alfred on Thursday, February 15. The insider PANGIA ROBERT W sold $1.92 million.

Investors sentiment increased to 1.17 in Q4 2017. Its up 0.04, from 1.13 in 2017Q3. It improved, as 46 investors sold Biogen Inc. shares while 305 reduced holdings. 105 funds opened positions while 305 raised stakes. 180.65 million shares or 0.28% less from 181.16 million shares in 2017Q3 were reported. 31,803 are held by Avalon Ltd Llc. Fuller & Thaler Asset Management stated it has 16,528 shares or 0.06% of all its holdings. Ngam Advisors Limited Partnership holds 69,251 shares. Whittier Tru Company Of Nevada holds 0.44% or 15,992 shares in its portfolio. Clinton Gp reported 1,553 shares. Greenleaf Trust owns 907 shares. Plante Moran Fincl Advsr Ltd Com accumulated 0.06% or 315 shares. Arrow Financial has 0.37% invested in Biogen Inc. (NASDAQ:BIIB). California State Teachers Retirement Sys stated it has 0.23% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Guardian Life Insurance Of America accumulated 0.05% or 684 shares. Wesbanco Natl Bank holds 1,435 shares. 683 are held by Moneta Group Inv Advisors Limited Liability. Bbva Compass Comml Bank Inc reported 0.1% in Biogen Inc. (NASDAQ:BIIB). 18,675 are owned by Meritage Portfolio Mgmt. Swiss Bank stated it has 0.27% of its portfolio in Biogen Inc. (NASDAQ:BIIB).

Biogen Inc. (NASDAQ:BIIB) Ratings Chart